SEPN earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -42.22. Updated 2026-07-23.
Septerna (SEPN) Research Hub
Septerna (SEPN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 38.51 USD (+1.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -42.22, market cap 1.50B. This hub links to the full technical, earnings and options research available for SEPN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 38.51 USD (+1.42%) |
| 52-week range | 31.44 USD – 48.95 USD |
| Trend regime | Range |
| 14-day RSI | 49.3 (Neutral) |
| Trailing P/E | -42.22 |
| Market cap | 1.50B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for SEPN
Covered Call on SEPN: how it works, illustrative setup around the real 38.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SEPN: how it works, illustrative setup around the real 38.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SEPN: how it works, illustrative setup around the real 38.51 USD price, max profit/loss, breakeven and when to use it. Educational.
SEPN technical analysis: range, last 38.51 USD, RSI 49.3, 52w range 31.44 USD–48.95 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SEPN in?
Septerna (SEPN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SEPN in an uptrend or downtrend?
As of 2026-09-11, SEPN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SEPN's trailing P/E ratio?
SEPN's trailing P/E is -42.22, with a market cap of 1.50B. See the earnings research page for full valuation detail.
When does SEPN next report earnings?
SEPN is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.48 USD.